Femasys Adds Dr. Eichenbaum to Board, Strengthening Clinical and Financial Expertise
Femasys appointed Dr. Kenneth D. Eichenbaum, a board-certified anesthesiologist with over 20 years of biotech and medical device advisory experience and engineering and finance degrees from Penn and Wharton, to its Board of Directors to enhance strategic and financial oversight. The company also thanked outgoing director Joshua Silverman for his capital markets counsel during a critical growth phase.
1. Appointment of Dr. Kenneth D. Eichenbaum
Femasys has named Dr. Kenneth D. Eichenbaum to its Board of Directors. Dr. Eichenbaum is a board-certified anesthesiologist with clinical roles at Corewell Health William Beaumont and Trinity Health Oakland, a Stanford fellowship, an MD from Icahn School of Medicine, an engineering degree from the University of Pennsylvania and a finance degree from Wharton.
2. Strategic Implications
Dr. Eichenbaum’s 20+ years evaluating biotechnology and medical device companies and advising investment firms will bolster Femasys’ governance as it advances non-surgical fertility and permanent birth control products through pivotal trials and commercial partnerships in Europe and other markets.
3. Departure of Joshua Silverman
Femasys expressed gratitude to outgoing director Joshua Silverman for his capital markets perspective and strategic counsel, crediting his support during a period of important growth, development of patent-protected product innovations and expansion into key international markets.